Maxceed Capital

Maxceed Capital

Maxceed Capital was established in 2018 by a group of twelve partners whose family businesses supply capital, operating knowledge, and deal access. The firm maintains its headquarters in Taipei with additional offices in Xiamen, Hyderabad, and Chengdu. The investment program centers on direct equity positions in biotechnology, electric vehicles, and financial technology. Capital is committed through co-investments and SPVs rather than blind-pool funds. Confirmed holdings include Enimmune, a vaccine developer listed on Taiwan's emerging stock market, CellMax Life, a liquid-biopsy cancer-screening company, and Amity, an enterprise collaboration platform. Activity spans Taiwan, Singapore, India, and mainland China. The team of twelve professionals includes two general partners, a manager, and external legal and accounting advisers from K&L Gates and Deloitte. Adjacent vehicles consist of the partners' separate family operating companies and affiliated private-equity funds. No public record of a material operational event has appeared in the last twenty-four months. Maxceed Capital's structure ties investment decisions to the commercial needs of its limited partners' operating businesses, creating a sourcing and exit channel unavailable to pure financial investors. This linkage shapes both sector selection and the preference for B2B models that can be integrated or acquired by partner-controlled entities.